Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003403 · ClinicalTrials.gov registry record · Phase 1
GPX-100 in Treating Patients With Solid Tumors
A Phase 1 study, sponsored by Gem Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003403 is a Phase 1 study that has completed, run by Gem Pharmaceuticals.
The verdict
NCT00003403, a Phase 1 study, has completed, sponsored by Gem Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of GPX-100 in treating patients who have solid tumors.
Interventions
- DRUG GPX-100
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003403
The ClinicalTrials.gov registry entry for NCT00003403 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gem Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GPX-100 is the first listed.
NCT00003403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003403 about?
NCT00003403 is a clinical study titled "GPX-100 in Treating Patients With Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of GPX-100 in treating patients who have solid tumors.
What is the current status of trial NCT00003403?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-08.
What interventions are being tested in trial NCT00003403?
The interventions under investigation include: GPX-100 (DRUG).
Who is sponsoring clinical trial NCT00003403?
This trial is sponsored by Gem Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.